High-dose oral cholecalciferol (vitamin D3) supplementation significantly reduced disease activity in patients with clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS) in the randomized, controlled D-Lay MS trial. “Combined with data from previous studies on vitamin D as an add-on therapy, the results of the D-Lay MS trial, which show a stronger effect of … Read more
The National Institute for Health and Care Excellence (NICE) has recommended cladribine (Mavenclad, Merck Serono) for adults in England with relapsing-remitting multiple sclerosis (RRMS). This decision makes the NHS the first healthcare system in Europe to widely offer the at-home tablet for patients with active MS. The final draft guidance means cladribine is an option for … Read more
Modern disease-modifying drugs (DMTs) have revolutionized the treatment of relapsing-remitting multiple sclerosis (MS). However, their use during pregnancy has long been concerning. A study published in The Lancet Regional Health – Europe provides valuable insights into the safety of these medications during pregnancy, based on data from the German MS and Pregnancy Registry. This study … Read more